Inclusion Body Myositis
Inclusion Body Myositis (IBM) is a rare inflammatory muscle disease that leads to progressive weakness and wasting of the muscles, particularly affecting the arms and legs.
Inclusion Body Myositis: Ruxolitinib Treatment Study
We are investigating whether ruxolitinib can improve movement and muscle function in patients with Inclusion Body Myositis. The study also looks at safety and quality of life for participants.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 45 years old or older?
- Are you currently pregnant or breastfeeding?
- Can you walk for 6 minutes without help from another person?
- Do you have a diagnosis of Inclusion Body Myositis (IBM)?
- Are you taking any medications that could interact with ruxolitinib, like immunomodulatory drugs?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Jakavi
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Opzelura
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Universitaire De Toulouse
Centre de Référence des Maladies Neuromusculaires
Blagnac, France
Centre Hospitalier Universitaire De Bordeaux
Centre de Référence des Maladies Neuromusculaires
Bordeaux, France
Hospices Civils De Lyon
Centre de Référence des Maladies Neuromusculaires
Bron, France
Sponsor: Assistance Publique Hopitaux De Paris
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.